USPTO Examiner RUDDIE ELLIOT S - Art Unit 3785

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19232721APPARATUS FOR DISPENSING INHALANT MEDICAMENTJune 2025January 2026Allow710YesNo
19051883AIRTIGHT SEAL FOR PRESSURIZED HYPERBARIC CHAMBERFebruary 2025October 2025Allow810NoNo
19037898LOADING ASSEMBLY FOR INHALER AND INHALERJanuary 2025June 2025Allow410NoNo
18937637Portable Child Anti-choking First Aid EquipmentNovember 2024March 2025Allow400YesNo
18629590METHODS AND APPARATUS FOR HIGH GAS FLOWApril 2024October 2025Allow1800YesNo
18603017DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERYMarch 2024January 2025Allow1000NoNo
18594799AEROSOL DELIVERY SYSTEM AND METHODMarch 2024January 2026Allow2220NoNo
18439843SYSTEM AND METHOD FOR CONTROLLING AND MONITORING FLOW IN AN ENDOTRACHEAL TUBEFebruary 2024May 2025Allow1511NoNo
18422464MEDICAL DEVICE WITH ENERGY HARVESTING SYSTEMJanuary 2024March 2026Allow2531NoNo
18405343PATIENT INTERFACE AND ASPECTS THEREOFJanuary 2024November 2025Allow2210NoNo
18389897DEVICES, SYSTEMS, AND METHODS FOR PROVIDING INDIVIDUALIZED DELIVERY OF SUSPENDED MEDICATIONDecember 2023December 2024Allow1220YesNo
18391174AEROSOL GENERATING SYSTEM WITH PREVENTION OF CONDENSATE LEAKAGEDecember 2023July 2025Allow1911NoNo
18541997Venturi Inhalation DeviceDecember 2023May 2025Abandon1710NoNo
18541605Venturi Inhalation DeviceDecember 2023May 2025Abandon1710NoNo
18541371Inhalers and Related MethodsDecember 2023January 2025Allow1300YesNo
18515604MODULAR ELBOW FRAME ASSEMBLY FOR A VENTILATORNovember 2023December 2024Allow1321YesNo
18512906SMART VALVED HOLDING CHAMBERNovember 2023June 2025Allow1910NoNo
18509316HIGHLY PORTABLE GAS DELIVERY SYSTEMSNovember 2023June 2024Allow710YesNo
18386028Biometric and environmental monitoring and control systemNovember 2023January 2025Allow1510NoNo
18448477SENSING FOR RESPIRATORY CIRCUITSAugust 2023November 2024Allow1500NoNo
18350097OSCILLATING POSITIVE EXPIRATORY PRESSURE DEVICEJuly 2023January 2025Allow1820YesNo
18330040DETECTION AND MONITORING OF DOSAGE DELIVERY FOR VAPORIZED WAXES, SOLIDS OR VISCOUS OILS, AND CANNABINOIDSJune 2023June 2025Allow2410NoNo
18324948FILTERING FACEPIECE RESPIRATORMay 2023August 2025Allow2711YesNo
18317245DEVICES, SYSTEMS, AND METHODS FOR DRY POWDER THERAPIESMay 2023September 2025Allow2910NoNo
18195457ENDOTRACHEAL TUBE GUARD WITH OPTIONAL HOLDING SYSTEM AND OPTIONAL SENSORMay 2023September 2024Allow1710NoNo
18315437APPARATUS AND METHOD FOR PROVIDING GASES TO A USERMay 2023May 2025Allow2400NoNo
18309963DISPENSING DEVICE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RHINITISMay 2023April 2025Allow2300NoNo
18140846Biometric and Environmental Monitoring and Control SystemApril 2023September 2024Allow1700YesNo
18298080FILTERING FACEPIECE RESPIRATORApril 2023January 2026Allow3410YesNo
18131165MOUTHPIECE WITH FLAVORED ATTACHMENTApril 2023November 2024Allow1900YesNo
18128959BREATH INDICATORMarch 2023June 2025Allow2630YesNo
18185486SWIVEL ELBOW AND CONNECTOR ASSEMBLY FOR PATIENT INTERFACE SYSTEMSMarch 2023September 2025Allow3010YesNo
18025534BREATH ACTUATED NEBULIZERMarch 2023February 2026Allow3510NoNo
18117823DRY POWDER DRUG DELIVERY SYSTEM AND METHODSMarch 2023July 2024Allow1710NoNo
18173994PATIENT MONITORING APPARATUS AND METHODFebruary 2023February 2024Allow1110NoNo
18021343INHALERFebruary 2023February 2026Allow3600NoNo
18100836INTEGRATING ACOUSTIC RESONANCE WITH SLEEP APNEA THERAPYJanuary 2023July 2024Abandon1820NoNo
18156429METERED DOSE INHALER ADD-ON DEVICE, OBSERVANCE IMPROVEMENT SYSTEM AND METHOD FOR IMPROVING OBSERVANCE OF USE IN METERED DOSE INHALERSJanuary 2023March 2024Allow1400YesNo
18146298ASYMMETRICAL NASAL DELIVERY ELEMENTS AND FITTINGS FOR NASAL INTERFACESDecember 2022April 2025Allow2820NoNo
18083986Ventilator Adapter and Auxiliary Part ThereofDecember 2022December 2023Allow1211YesNo
18066721SYSTEMS AND METHODS FOR AN ULTRASONICALLY DRIVEN ANESTHETIC VAPORIZERDecember 2022December 2024Allow2400YesNo
17927230MEDICAL AGENT INHALERNovember 2022December 2025Allow3610YesNo
17984372Biometric and Environmental Monitoring and Control SystemNovember 2022February 2025Allow2710NoNo
17975708CPAP FLOW DRIVER FOR USING NEBULIZER WITH CPAP APPARATUSOctober 2022December 2024Abandon2611NoNo
17921777COVER ASSEMBLY AND ACTUATOR FOR INHALEROctober 2022January 2026Abandon3910NoNo
17968291SMART NEBULIZEROctober 2022July 2025Allow3311YesNo
17965037TEXTILE SEAL WITH AIR-ASSISTED BIASING PORTIONOctober 2022March 2024Allow1700NoNo
17929538INTRANASAL COMPOSITION OF PHARMACEUTICAL COUNTERMEASURES FOR CHEMICAL WARFARE NERVE AGENTS AND ACCIDENTAL EXPOSURE TO ORGANOPHOSPHATE PESTICIDESSeptember 2022June 2024Allow2210NoNo
17802403PORTABLE VENTILATORAugust 2022May 2025Allow3300YesNo
17887430SYSTEMS FOR INHALATION OF THERAPEUTIC AND DIAGNOSTIC GAS AND METHODS OF USE THEREOFAugust 2022February 2024Allow1810YesNo
17886853PATIENT INTERFACEAugust 2022February 2026Allow4310YesNo
17798883DEVICE FOR INHALING POWDERED ACETYLSALICYCLIC ACID AND RELATIVE USE THEREOFAugust 2022January 2026Abandon4110NoNo
17884417RESPIRATORY THERAPY FILTER, FLOW CONTROL, AND PATIENT INTERFACE APPARATUSES, SYSTEMS, AND METHODSAugust 2022October 2025Allow3830YesNo
17883119METERED DOSE INHALER WITH MOUTHPIECE EXTENSIONAugust 2022November 2025Allow3900YesNo
17798054DRUG DELIVERY HUB FOR VENTILATION MASKAugust 2022November 2025Abandon4010YesNo
17873662Dry Powder Medicament InhalerJuly 2022December 2025Abandon4021YesYes
17794660DRY POWDER INHALERS AND INTERFACES FOR IMPROVED AEROSOL DELIVERY TO CHILDRENJuly 2022December 2025Allow4010YesNo
17869380METHODS FOR MEASURING DOSE CONTENT UNIFORMITY PERFORMANCE OF INHALER AND NASAL DEVICESJuly 2022November 2023Allow1610NoNo
17863527Medical TubeJuly 2022April 2024Abandon2130NoNo
17858704SEAL FOR A PATIENT INTERFACE, INTERFACE ASSEMBLIES AND ASPECTS THEREOFJuly 2022January 2025Allow3120NoNo
17857862METHODS AND APPARATUS FOR HIGH GAS FLOWJuly 2022February 2024Allow1920YesNo
17857686AEROSOL GENERATING SYSTEM WITH PREVENTION OF CONDENSATE LEAKAGEJuly 2022September 2023Allow1410NoNo
17849223SMART VALVED HOLDING CHAMBERJune 2022August 2023Allow1410YesNo
17847968Inhalers and Related MethodsJune 2022August 2023Allow1410YesNo
17787710PATIENT INTERFACE WITH FOAM CUSHIONJune 2022December 2025Allow4210YesNo
17784949PRODUCT DISPENSING DEVICEJune 2022October 2025Abandon4110NoNo
17785002Mouthpiece For A Product Dispensing DeviceJune 2022October 2025Abandon4110NoNo
17835670OSCILLATING POSITIVE EXPIRATORY PRESSURE DEVICEJune 2022September 2025Allow3910YesNo
17834303DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODYJune 2022December 2025Allow4210YesNo
17831634FILTERING FACEPIECE RESPIRATORJune 2022February 2023Allow911YesNo
17828669TUB FOR USE IN A HUMIDIFIERMay 2022March 2026Allow4530YesYes
17750695Terpene InhalantMay 2022October 2025Abandon4110NoNo
17746251MEASUREMENT DEVICE AND METHOD FOR MONITORING CONDITION OF PATIENTMay 2022December 2022Allow711YesNo
17738285SYSTEMS AND METHODS FOR HIGH VELOCITY NASAL INSUFFLATIONMay 2022November 2025Allow4330NoNo
17725396FacemaskApril 2022January 2023Abandon910NoNo
17695544VAPORIZABLE SUBSTANCE STORAGE DEVICEMarch 2022October 2024Abandon3130YesNo
17641751ORO-NASAL PATIENT INTERFACEMarch 2022October 2023Allow2020YesNo
17639228DUAL CHAMBER PATIENT INTERFACE WITH AIRFLOW REGULATIONFebruary 2022January 2026Allow4710YesNo
17652393CONTROL OF FLOW AND/OR PRESSURE PROVIDED BY BREATHING APPARATUSFebruary 2022November 2025Allow4550YesNo
17665902DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERYFebruary 2022December 2023Allow2220YesNo
17666099ATOMIZER FOR NASAL THERAPYFebruary 2022September 2025Allow4340NoNo
17568277SWIVEL ELBOW AND CONNECTOR ASSEMBLY FOR PATIENT INTERFACE SYSTEMSJanuary 2022December 2022Allow1120YesNo
17559850PATIENT INTERFACE WITH FOAM SEAL-FORMING STRUCTUREDecember 2021October 2024Allow3410YesNo
17558296CONTROL OF FLOW AND/OR PRESSURE PROVIDED BY BREATHING APPARATUSDecember 2021March 2024Allow2720YesNo
17557752VentilatorDecember 2021July 2025Allow4310NoNo
17551607Biometric and environmental monitoring and control systemDecember 2021July 2023Allow1910NoNo
17542753ASSISTIVE DEVICE FOR AN INHALERDecember 2021August 2025Allow4410NoNo
17453111INHALANT DISPENSING SYSTEM AND APPARATUSNovember 2021September 2024Abandon3501NoNo
17511155OROPHRANGEAL GLOVE FOR USE WITH RIGID AND FLEXIBLE BRONCHSCOPES, AND METHODSOctober 2021November 2025Abandon4910NoNo
17451239PRESSURIZING MASKS, SYSTEMS AND METHODSOctober 2021June 2024Allow3230NoNo
17599401COLLAPSIBLE, DISPOSABLE MEDICATION INHALATION SPACER AND METHODSeptember 2021January 2023Allow1511YesNo
17471931PHARYNGEAL RESPIRATORSSeptember 2021February 2022Allow500YesNo
17430163TEXTILE SEAL WITH AIR-ASSISTED BIASING PORTIONAugust 2021June 2022Allow1010YesNo
17396588COMPACT PORTABLE OXYGEN CONCENTRATORAugust 2021June 2025Allow4730YesNo
17394969METHOD AND APPARATUS FOR ORAL FLOW THERAPYAugust 2021July 2024Abandon3610NoNo
17371756Floatable Breathing DeviceJuly 2021April 2025Allow4500YesNo
17368891NASAL MASK SYSTEMJuly 2021May 2025Abandon4731YesNo
17356830Venturi Inhalation DeviceJune 2021September 2023Allow2721YesNo
17354980MASK/RESPIRATOR WITH MICROPHONEJune 2021August 2022Abandon1411YesNo
17344625Device for Dispensing Medication for Migraine TreatmentJune 2021November 2025Allow5310YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RUDDIE, ELLIOT S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
2
(28.6%)
Examiner Reversed
5
(71.4%)
Reversal Percentile
88.7%
Higher than average

What This Means

With a 71.4% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
14
Allowed After Appeal Filing
7
(50.0%)
Not Allowed After Appeal Filing
7
(50.0%)
Filing Benefit Percentile
84.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner RUDDIE, ELLIOT S - Prosecution Strategy Guide

Executive Summary

Examiner RUDDIE, ELLIOT S works in Art Unit 3785 and has examined 269 patent applications in our dataset. With an allowance rate of 69.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner RUDDIE, ELLIOT S's allowance rate of 69.5% places them in the 31% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by RUDDIE, ELLIOT S receive 2.14 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RUDDIE, ELLIOT S is 38 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +47.6% benefit to allowance rate for applications examined by RUDDIE, ELLIOT S. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.5% of applications are subsequently allowed. This success rate is in the 44% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 31.4% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 58.8% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 30.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 18.2% are granted (fully or in part). This grant rate is in the 10% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 47% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.